| Medical and Health Sciences | Lifetime | 162 | US 89 | 99.99 |
| Biological Sciences | Lifetime | 145 | US 87 | 99.98 |
| Pharmacology | Lifetime | 1 | US 1 | 99.99 |
| Molecular Biology | Lifetime | 84 | US 63 | 99.97 |
| Oncology | Lifetime | 69 | US 35 | 99.88 |
| Biochemistry | Lifetime | 26 | US 16 | 99.61 |
| Cancer Research | Lifetime | 60 | US 34 | 99.71 |
| Epidemiology | Lifetime | 882 | US 445 | 98.82 |
| Medical Physiology | Lifetime | 990 | US 496 | 98.11 |
| Health, Toxicology and Mutagenesis | Lifetime | 537 | US 196 | 97.72 |
| Clinical Biochemistry | Lifetime | 252 | US 119 | 95.59 |
| Hepatology | Lifetime | 746 | US 278 | 86.51 |
| Molecular Biology | 2021-2025 | 308 | US 83 | 98.62 |
| Epidemiology | 2021-2025 | 676 | US 237 | 93.61 |
| Oncology | 2021-2025 | 499 | US 220 | 93.34 |
| Drug Transport and Resistance Mechanisms | Lifetime | 1 | US 1 | 99.99 |
| Pharmacogenetics and Drug Metabolism | Lifetime | 1 | US 1 | 99.99 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 1 | US 1 | 99.97 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 4 | US 2 | 99.92 |
| Carcinogens and Genotoxicity Assessment | Lifetime | 7 | US 6 | 99.86 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 32 | US 17 | 99.84 |
| Chemical Reactions and Isotopes | Lifetime | 9 | US 7 | 99.63 |
| Metabolomics and Mass Spectrometry Studies | Lifetime | 23 | US 12 | 99.76 |
| Adipose Tissue and Metabolism | Lifetime | 54 | US 32 | 99.79 |
| Liver Disease Diagnosis and Treatment | Lifetime | 87 | US 31 | 99.84 |
| Metabolism, Diabetes, and Cancer | Lifetime | 28 | US 16 | 99.79 |
| Drug-Induced Hepatotoxicity and Protection | Lifetime | 20 | US 11 | 99.74 |
| Glutathione Transferases and Polymorphisms | Lifetime | 9 | US 5 | 99.62 |
| Metabolism and Genetic Disorders | Lifetime | 66 | US 28 | 99.52 |
| Cancer, Lipids, and Metabolism | Lifetime | 77 | US 42 | 99.59 |
| Hormonal Regulation and Hypertension | Lifetime | 129 | US 55 | 99.27 |
| Molecular Biology Techniques and Applications | Lifetime | 107 | US 67 | 98.84 |
| Epigenetics and DNA Methylation | Lifetime | 314 | US 183 | 99.10 |
| Alcohol Consumption and Health Effects | Lifetime | 96 | US 54 | 98.82 |
| Inflammatory mediators and NSAID effects | Lifetime | 130 | US 71 | 98.98 |
| Effects and risks of endocrine disrupting chemicals | Lifetime | 140 | US 51 | 99.00 |
| Genomics, phytochemicals, and oxidative stress | Lifetime | 112 | US 44 | 98.61 |
| Pancreatic function and diabetes | Lifetime | 336 | US 155 | 98.94 |
| Pediatric Hepatobiliary Diseases and Treatments | Lifetime | 171 | US 65 | 98.80 |
| Cholesterol and Lipid Metabolism | Lifetime | 105 | US 55 | 98.46 |
| Estrogen and related hormone effects | Lifetime | 346 | US 220 | 98.63 |
| Liver physiology and pathology | Lifetime | 192 | US 77 | 98.20 |
| Pharmacological Effects and Toxicity Studies | Lifetime | 333 | US 132 | 98.25 |
| Toxic Organic Pollutants Impact | Lifetime | 310 | US 79 | 98.65 |
| Cancer therapeutics and mechanisms | Lifetime | 351 | US 201 | 98.12 |
| Diet and metabolism studies | Lifetime | 976 | US 410 | 98.34 |
| Gut microbiota and health | Lifetime | 695 | US 231 | 97.78 |
| Synthesis and Biological Evaluation | Lifetime | 658 | US 184 | 96.83 |
| Cancer Treatment and Pharmacology | Lifetime | 964 | US 457 | 97.44 |
| Fibroblast Growth Factor Research | Lifetime | 268 | US 120 | 96.10 |
| Retinoids in leukemia and cellular processes | Lifetime | 600 | US 308 | 95.53 |
| Lipid metabolism and biosynthesis | Lifetime | 661 | US 268 | 94.81 |
| Nuclear Receptors and Signaling | Lifetime | 466 | US 220 | 94.09 |
| Lipid metabolism and disorders | Lifetime | 784 | US 271 | 92.81 |
| NF-κB Signaling Pathways | Lifetime | 991 | US 386 | 92.59 |
| Kruppel-like factors research | Lifetime | 540 | US 205 | 91.24 |
| Biosimilars and Bioanalytical Methods | Lifetime | 913 | US 336 | 89.06 |
| Plant-derived Lignans Synthesis and Bioactivity | Lifetime | 545 | US 68 | 82.60 |
| Ginger and Zingiberaceae research | Lifetime | 886 | US 58 | 78.54 |
| Natural Compounds in Disease Treatment | Lifetime | 518 | US 60 | 73.36 |
| Peroxisome Proliferator-Activated Receptors | 2021-2025 | 1 | US 1 | 98.91 |
| Drug Transport and Resistance Mechanisms | 2021-2025 | 4 | US 2 | 98.92 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 337 | US 77 | 98.32 |
| Drug-Induced Hepatotoxicity and Protection | 2021-2025 | 246 | US 42 | 87.66 |
| Liver physiology and pathology | 2021-2025 | 352 | US 53 | 80.69 |
| Liver Diseases and Immunity | 2021-2025 | 679 | US 156 | 81.25 |
| Phytochemicals and Medicinal Plants | 2021-2025 | 458 | US 28 | 71.74 |
| Pharmacogenetics and Drug Metabolism | 2021-2025 | 981 | US 288 | 66.62 |
| Sphingolipid Metabolism and Signaling | 2021-2025 | 765 | US 205 | 57.15 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 851 | US 223 | 55.81 |
| Polyamine Metabolism and Applications | 2021-2025 | 833 | US 74 | 51.01 |
| Public Health and Environmental Issues | 2021-2025 | 599 | US 17 | 37.32 |
